Revolutionary Blood Test Detects Deadly Brain Cancer in Just One Hour

SciFocus/Sept 3, 2024 -- A groundbreaking new blood test promises to revolutionize brain cancer diagnosis, providing rapid and non-invasive detection of glioblastoma, the deadliest form of brain tumor. Developed by a team of scientists from the University of Notre Dame and their international partners, this test can identify cancer biomarkers in just one hour with remarkable accuracy, potentially offering a faster, safer alternative to traditional biopsies.

Key Highlights:

- Rapid Diagnosis: The test requires only 100 microliters of blood and can detect glioblastoma biomarkers within an hour.

- High Accuracy: Utilizes a biochip costing less than $2, which accurately detects and quantifies exosome concentrations linked to glioblastoma.

- Innovation in Cancer Detection: Targets mutated epidermal growth factor receptors (EGFRs) within extracellular vesicles, a novel approach to identifying brain cancer.

- Minimal Invasiveness: Offers a non-invasive alternative to surgical biopsies, potentially reducing risks and improving patient comfort.

- Broader Implications: While currently focused on glioblastoma, the test could be adapted to detect other cancers and monitor disease progression.

This breakthrough not only represents a significant advancement in cancer diagnostics but also opens new avenues for early detection and treatment across various forms of cancer. The findings were published in Communications Biology.

If you're enjoying this content, sign up to SciFocus daily newsletter by Biopatrika for all the biggest stories in Science, healthcare, STEM, startups, and how we're advocating to "Bring Science to Society." #SciFocus #Biopatrika

For partnership or advertisement opportunities, feel free to contact us here or visit www.biopatrika.com.

Career Opportunities: Biopatrika Career Hub https://www.dhirubhai.net/groups/13946324/

Follow Virender Singh and Biopatrika on LinkedIn.